SEGMENT INFORMATION (Tables)
|
12 Months Ended |
Oct. 31, 2017 |
|---|
| Revenue from External Customer [Line Items] |
|
| Segment profitability |
The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below. | | | | | | | | | | | | | | | | | | Life Sciences and Applied Markets | | Diagnostics and Genomics | | Agilent CrossLab | | Total Segments | | (in millions) | Year ended October 31, 2017: | | | | | | | | Total net revenue | $ | 2,169 |
| | $ | 772 |
| | $ | 1,531 |
| | $ | 4,472 |
| Income from operations | $ | 487 |
| | $ | 149 |
| | $ | 338 |
| | $ | 974 |
| Depreciation expense | $ | 35 |
| | $ | 30 |
| | $ | 29 |
| | $ | 94 |
| Share-based compensation expense | $ | 30 |
| | $ | 10 |
| | $ | 21 |
| | $ | 61 |
| Year ended October 31, 2016: | | | | | | | | Total net revenue | $ | 2,073 |
| | $ | 709 |
| | $ | 1,420 |
| | $ | 4,202 |
| Income from operations | $ | 429 |
| | $ | 114 |
| | $ | 316 |
| | $ | 859 |
| Depreciation expense | $ | 36 |
| | $ | 31 |
| | $ | 28 |
| | $ | 95 |
| Share-based compensation expense | $ | 29 |
| | $ | 10 |
| | $ | 21 |
| | $ | 60 |
| Year ended October 31, 2015: | | | | | | | | Total net revenue | $ | 2,046 |
| | $ | 662 |
| | $ | 1,330 |
| | $ | 4,038 |
| Income from operations | $ | 380 |
| | $ | 88 |
| | $ | 299 |
| | $ | 767 |
| Depreciation expense | $ | 27 |
| | $ | 37 |
| | $ | 34 |
| | $ | 98 |
| Share-based compensation expense | $ | 27 |
| | $ | 9 |
| | $ | 18 |
| | $ | 54 |
|
|
| Reconciliation of segment results to total enterprise results |
The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes:
| | | | | | | | | | | | | | Years Ended October 31, | | 2017 | | 2016 | | 2015 | | (in millions) | Total reportable segments' income from operations | $ | 974 |
| | $ | 859 |
| | $ | 767 |
| Business exit and divestiture costs ( primarily our NMR business) | — |
| | (11 | ) | | (12 | ) | Asset Impairments | — |
| | (4 | ) | | (3 | ) | Transformational initiatives | (12 | ) | | (38 | ) | | (56 | ) | Amortization of intangible assets related to business combinations | (117 | ) | | (152 | ) | | (156 | ) | Acquisition and integration costs | (30 | ) | | (41 | ) | | (13 | ) | Acceleration of share-based compensation expense related to workforce reduction | — |
| | — |
| | (2 | ) | Pension curtailment gain | — |
| | 15 |
| | — |
| Pension settlement gain | 32 |
| | 1 |
| | — |
| Impairment of loans | — |
| | (7 | ) | | — |
| Other | (6 | ) | | (7 | ) | | (3 | ) | Interest Income | 22 |
| | 11 |
| | 7 |
| Interest Expense | (79 | ) | | (72 | ) | | (66 | ) | Other income (expense), net | 19 |
| | (10 | ) | | 17 |
| Income from continuing operations before taxes, as reported | $ | 803 |
| | $ | 544 |
| | $ | 480 |
|
|
| Assets and capital expenditures directly managed by each segment |
The following table presents assets and capital expenditures attributed to each segment. Unallocated assets primarily consist of cash, cash equivalents, accumulated amortization of other intangibles and other assets.
| | | | | | | | | | | | | | | | | | Life Sciences and Applied Markets | | Diagnostics and Genomics | | Agilent CrossLab | | Total Segments | | (in millions) | As of October 31, 2017: | | | | | | | | Assets | $ | 1,753 |
| | $ | 2,119 |
| | $ | 1,138 |
| | $ | 5,010 |
| Capital expenditures | $ | 39 |
| | $ | 111 |
| | $ | 26 |
| | $ | 176 |
| As of October 31, 2016: | | | | | | | | Assets | $ | 1,687 |
| | $ | 1,960 |
| | $ | 1,082 |
| | $ | 4,729 |
| Capital expenditures | $ | 53 |
| | $ | 41 |
| | $ | 45 |
| | $ | 139 |
|
The following table reconciles segment assets to Agilent's total assets:
| | | | | | | | | | October 31, | | 2017 | | 2016 | | (in millions) | Total reportable segments' assets | $ | 5,010 |
| | $ | 4,729 |
| Cash, cash equivalents | 2,678 |
| | 2,289 |
| Prepaid expenses | 92 |
| | 92 |
| Investments | 138 |
| | 135 |
| Long-term and other receivables | 105 |
| | 92 |
| Other | 403 |
| | 457 |
| Total assets | $ | 8,426 |
| | $ | 7,794 |
|
|
| Revenue by product category |
The following table represents total revenue by product category: | | | | | | | | | | | | | | Years Ended October 31, | | 2017 | | 2016 | | 2015 | | (in millions) | Instrumentation | $ | 1,946 |
| | $ | 1,871 |
| | $ | 1,827 |
| Analytical lab services | 991 |
| | 910 |
| | 843 |
| Analytical lab consumables | 540 |
| | 510 |
| | 489 |
| Diagnostics and genomics solutions | 772 |
| | 709 |
| | 662 |
| Informatics and other | 223 |
| | 202 |
| | 217 |
| Total | $ | 4,472 |
| | $ | 4,202 |
| | $ | 4,038 |
|
|
| Revenue and assets by geographic areas |
The following table presents summarized information for net revenue and long-lived assets by geographic region. Revenues from external customers are generally attributed to countries based upon the customer's location. Long lived assets consist of property, plant, and equipment, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of rest of Asia and Europe.
| | | | | | | | | | | | | | | | | | United States | | China(1) | | Rest of the World | | Total | | (in millions) | Net revenue: | | | | | | | | Year ended October 31, 2017 | $ | 1,314 |
| | $ | 900 |
| | $ | 2,258 |
| | $ | 4,472 |
| Year ended October 31, 2016 | $ | 1,251 |
| | $ | 839 |
| | $ | 2,112 |
| | $ | 4,202 |
| Year ended October 31, 2015 | $ | 1,214 |
| | $ | 693 |
| | $ | 2,131 |
| | $ | 4,038 |
|
| | 1. | China also includes Hong Kong net revenue. Prior periods have been revised to conform with current year presentation. |
| | | | | | | | | | | | | | | | | | United States | | Germany | | Rest of the World | | Total | | (in millions) | Long-lived assets: | | | | | | | | October 31, 2017 | $ | 556 |
| | $ | 118 |
| | $ | 358 |
| | $ | 1,032 |
| October 31, 2016 | $ | 449 |
| | $ | 89 |
| | $ | 266 |
| | $ | 804 |
|
|